Horsham, PA, May 2, 2024 – Myonex, a global leader in clinical trial supply solutions, has successfully completed the previously announced acquisition of Creapharm’s pharmaceutical services business. With this transaction, Myonex enhances its capabilities to serve pharmaceutical and biotech companies in both clinical and commercial stages, including those managing Advanced Therapies.
The distribution and clinical packaging services, commercial packaging operations, and bioservices previously offered by Creapharm will now operate under the name Creapharm, a Myonex company. This consolidation brings together expertise and flexibility to meet the evolving needs of clients with agility, flexibility, and reliability.
“We are thrilled to have completed the acquisition of Creapharm, a significant milestone that expands our services and strengthens our capabilities for clients and the industry. Together, we are well-positioned to meet the dynamic needs of our clients with excellence and innovation,” said James Lovett, CEO of Myonex.
Eric Placet, the visionary founder and former CEO of Creapharm, will join Myonex’s board of directors, reaffirming his commitment to excellence and innovation. Additionally, Carla Da Costa has been appointed as the Director of Operations, further bolstering the executive team and driving growth while providing exceptional value to clients.
Myonex received advisory support from McDermott, Will & Emery in France, Troutman Pepper in the United States for legal counsel, and Crosstree Capital Partners as a financial advisor in the acquisition of Creapharm. Creapharm was advised in France by ARST Avocats for legal mergers and acquisitions and Nomodos for fiscal and corporate legal matters. Nelson Mullins acted as the US legal advisor, with Rothschild & Co serving as the financial advisor.
About Myonex:
Myonex is a global leader in comprehensive clinical trial supply, offering tailored solutions in drug sourcing, packaging, labeling, and central and local equipment and accessory supply to support the specific requirements and complexities of each trial. With locations in the USA, Germany, and the UK, we partner with pharmaceutical and biotech companies, contract research organizations (CROs), and other clinical trial service providers seeking a flexible and integrated supply solution for their trial needs. Learn more at www.myonex.com
About Creapharm:
With decades of experience in global clinical trial supply management, Creapharm provides customized solutions to key players in the pharmaceutical and biotech industries. Creapharm specializes in cold chain management and has recently developed ultra-cold solutions for handling biological products and ATMP supply chain management. For marketed healthcare products, Creapharm offers expert commercial packaging services to the pharmaceutical and dietary supplement industries. Learn more at www.creapharm-pharma.com
Contact:
Maryanne Walsh
(+1) 267-307-0876
Logo – https://mma.prnewswire.com/media/2381955/4683277/MYONEX_RGB__1_Logo.jpg
The acquisition of Creapharm’s pharmaceutical services business by Myonex expands the capabilities of Myonex in serving pharmaceutical and biotech companies in both clinical and commercial stages, including those managing Advanced Therapies. This consolidation brings together expertise and flexibility to meet the evolving needs of clients with agility, flexibility, and reliability.
One advantage of this acquisition is that it enhances Myonex’s services and strengthens its capabilities in the pharmaceutical industry. By combining the distribution and clinical packaging services, commercial packaging operations, and bioservices previously offered by Creapharm under the name Creapharm, a Myonex company, the company can provide a more comprehensive range of services to its clients.
Another advantage is the addition of Eric Placet, the founder and former CEO of Creapharm, to Myonex’s board of directors. Placet’s expertise and experience will contribute to the continued excellence and innovation of the company.
However, there may also be challenges and controversies associated with the acquisition. Integrating the operations and teams of the two companies may require careful management to ensure a smooth transition and maintain client satisfaction. Additionally, there may be concerns about potential changes in the quality or reliability of services as a result of the consolidation.
In terms of current market trends, there is a growing demand for comprehensive clinical trial supply solutions. Pharmaceutical and biotech companies are increasingly seeking integrated supply solutions that can accommodate the specific requirements and complexities of each trial. Myonex’s acquisition of Creapharm positions the company to meet this demand and provide tailored solutions to its clients.
Looking ahead, the market for clinical trial supply is expected to continue growing. The increasing focus on advanced therapies, such as gene and cell therapies, presents opportunities for companies like Myonex that have the capabilities to support these innovative treatments. Additionally, the ongoing globalization of clinical trials and the need for cold chain management for biological products are driving factors in the market.
Some key challenges in the market include regulatory complexities and the need for stringent quality control measures. The pharmaceutical industry is heavily regulated, and companies must navigate various guidelines and requirements to ensure compliance. Maintaining high quality standards throughout the clinical trial supply process is crucial for the success and safety of trials.
For more information about Myonex, visit their website at www.myonex.com. To learn more about Creapharm, visit www.creapharm-pharma.com.